Last reviewed · How we verify
Systemic erythropoietin injection
At a glance
| Generic name | Systemic erythropoietin injection |
|---|---|
| Also known as | Eprax 10000 |
| Sponsor | Alexandria University |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Systemic Erythropoietin Injection in Patients Having Optic Atrophy (PHASE1, PHASE2)
- Subcutaneous Injection of Erythropoietin on Visual Functions in Patients With Late Onset Optic Neuropathy (PHASE1, PHASE2)
- Cross Iron (Comparative Randomized Oral Versus Systemic IRON) (NA)
- Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With Cancer (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Systemic erythropoietin injection CI brief — competitive landscape report
- Systemic erythropoietin injection updates RSS · CI watch RSS
- Alexandria University portfolio CI